Wire · opportunities
Roche's Sefaxersen Meets Primary Endpoint in Phase 3 IgAN Study
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 September 2026 · Fusion42 review
Roche's antisense oligonucleotide drug sefaxersen met the primary endpoint by significantly reducing proteinuria in the Phase 3 IMAgINATION IgAN trial, showing potential regulatory relevance. The drug targets the complement alternative pathway upstream of existing therapies, differentiating its mechanism with ongoing data awaited to confirm full efficacy and safety.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 23 Sep 2026 and 25 Sep 2026.
◆ ◆ The Wire takeaway
Roche's drug opens a new approach to IgAN treatment targeting upstream complement pathways, challenging existing therapies. You should watch the full data release to gauge whether your kidney disease patients now have a meaningful alternative therapy option.
◆ Coverage
3 sources · first reported 23 Sep 2026 · latest 25 Sep 2026
◆ Related on Wire
◆ Topics